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Abstract
Introduction: AIDS-mortality remains unacceptably high in sub-Saharan Africa, largely driven by advanced HIV disease (AHD).
We nested a study in an existing tuberculosis (TB) contact-tracing intervention (Xpatial-TB). The aim was to assess the burden
of AHD among high-risk people living with HIV (PLHIV) identified and to evaluate the provision of the WHO-recommended
package of care to this population.
Methods: All PLHIV ≥14 years old identified between June and December 2018 in Manhica District by Xpatial-TB were
offered to participate in the study if ART na€ıve or had suboptimal ART adherence. Consenting individuals were screened for
AHD. Patients with AHD (CD4 < 200 cells/lL or WHO stage 3 or 4) were offered a package of interventions in a single visit,
including testing for cryptococcal antigen (CrAg) and TB-lipoarabinomannan (TB-LAM), prophylaxis and treatment for oppor-
tunistic infections, adherence support or accelerated ART initiation. We collected information on follow-up visits carried out
under routine programmatic conditions for six months.
Results: A total of 2881 adults were identified in the Xpatial TB-contact intervention. Overall, 23% (673/2881) were HIV pos-
itive, including 351 TB index (64.2%) and 322 TB contacts (13.8%). Overall, 159/673 PLHIV (24%) were ART na€ıve or had
suboptimal ART adherence, of whom 155 (97%, 124 TB index and 31 TB-contacts) consented to the study and were screened
for AHD. Seventy percent of TB index-patients (87/124) and 16% of TB contacts (5/31) had CD4 < 200 cells/µL. Four (13%)
of the TB contacts had TB, giving an overall AHD prevalence among TB contacts of 29% (9/31). Serum-CrAg was positive in
4.6% (4/87) of TB-index patients and in zero TB contacts. All ART na€ıve TB contacts without TB initiated ART within 48 hours
of HIV diagnosis. Among TB cases, ART timing was tailored to the presence of TB and cryptococcosis. Six-month mortality
was 21% among TB-index cases and zero in TB contacts.
Conclusions: A TB contact-tracing outreach intervention identified undiagnosed HIV and AHD in TB patients and their con-
tacts, undiagnosed cryptococcosis among TB patients, and resulted in an adequate provision of the WHO-recommended pack-
age of care in this rural Mozambican population. Same-day and accelerated ART initiation was feasible and safe in this
population including among those with AHD.
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1 | INTRODUCTION
Despite the reduction in HIV incidence and AIDS-mortality
resulting from expanded access to antiretroviral treatment
(ART) globally, more than one-third of people living with HIV
(PLHIV) continue to present to care with advanced HIV dis-
ease (AHD) in many low and middle income countries [1-3].
AHD is defined as having <200 CD4 cells/lL or World Health
Organization (WHO) clinical stage 3 or 4 criteria [4]. People
presenting with AHD are at high risk of opportunistic
infections (OI), hospitalizations and mortality with tuberculosis
(TB) and cryptococcosis accounting for the majority of these
AIDS-related deaths [5-12].
In 2015, the WHO called for differentiated care service-
delivery for various HIV populations [6,13-15]. Two years later
specific guidelines for managing AHD were released [4]. These
promote offering PLHIV a “package of interventions” including
rapid OI screening, prompt OI prophylaxis/treatment and
accelerated ART initiation. They include a decision-making
guide to assist clinicians in rapid implementation of these
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measures, since the need for repeated visits has proved to
increase pre-ART attrition [16-18]. In this sense, point-of-care
(POC) diagnostics are recommended to allow for patient-
centred services in a single-visit even in remote healthcare
settings [16,19,20]. Although there is a growing body of evi-
dence supporting the benefit of these interventions, their
translation into practice remains limited [14,15,21,22].
In January 2018, the Centro de Investigac~ao em Saude de
Manhica (CISM; Manhica Health Research Centre), in collabo-
ration with the National Tuberculosis Program (NTP) officers
in the Manhica District of Southern Mozambique began imple-
menting a project named Xpatial-TB. This project assessed a
novel community-based, TB active case-finding (TB-ACF) strat-
egy among risk-stratified adult and child contacts of all newly
diagnosed TB cases registered in the district.
Ancillary to the Xpatial-TB study, we nested a study with
two objectives: (i) assessing the burden of AHD among high-
risk HIV-positive adults identified through Xpatial-TB; (ii) eval-
uating the implementation of the WHO-recommended pack-
age of care among PLHIV with AHD [4].
2 | METHODS
2.1 | Xpatial-TB (TB-contact tracing) intervention
In 2018, incident TB cases (either pulmonary or extrapul-
monary) registered in any TB diagnostic unit in the district
and their household and community contacts of any age were
visited. These were defined as population living within radios
of 40, 70 or 120 m from the index case, depending on the
cycle threshold (Ct) values of their Xpert MTB/RIF Ultra
(Ultra) result and population density. Tracing was done using
the information provided by the existing Health and Demo-
graphic Surveillance System (HDSS), which covers the whole
Manhica district. Xpatial-TB field workers interviewed TB
cases and contacts about their HIV-status, offered HIV coun-
selling and testing (HCT). In addition, among those contacts
HIV positive or with a positive WHO-four symptom screening
(WHO-4SS, any duration of cough, fever, night sweats or
weight loss), a sputum sample was obtained through a porta-
ble nebulizer as needed. All contacts ≤14 years old were
booked at the Xpatial-TB study clinic for clinical evaluation
including further sampling (nasopharyngeal and/or gastric aspi-
rate, stool) and a chest X-ray for those ≤5 years old. Adult
contacts newly diagnosed with HIV positive and/or TB posi-
tive were given a referral letter to the health system.
2.2 | Study intervention
From 28 May to 31 December 2018, consenting
PLHIV ≥ 14 years old reached by Xpatial-TB were offered to
participate in this ancillary study if they had been newly diag-
nosed with HIV, were ART interrupters or had poor ART
adherence regardless of the Xpatial-TB status (TB index or
contacts). Upon acceptance, a study counsellor visited the con-
senting participants within 24 hours and offered them a
home-counselling session followed by transport to the study
clinic, where a clinical officer provided: (i) Clinical evaluation,
including the assessment of danger signs (heart rate
>120 beats per minute, respiratory rate >30 breaths per min-
ute, systolic blood pressure <90 mmHg, body temperature
>39 Celsius, moderate or severe dehydration, bedridden or
needing aid to walk, altered mental state, other neurological
problem); (ii) WHO HIV clinical staging; (iii) venous sampling
for CD4 cell counts (BD FACS Calibur, BD Biosciences, Frank-
lin Lakes, NJ, USA) and baseline pre-ART safety liver and kid-
ney biochemistry analysis; (iv) a reflex cryptococcal antigen
lateral flow assay (CrAg-LFA, Immuno-Mycologics, Inc., OK,
USA) that was performed in the laboratory if <200 CD4 cells/
lL; (v) a urine tuberculosis lateral flow lipoarabinomannan test
(TB-LAM, Alere Inc., Waltham, MA, USA) done if any danger
sign was present or <200 CD4 cells/lL and (vi) a digital chest
X-Ray (CXR). Of note, CrAg-screening and TB-LAM were not
routine of care in the district at the time. The latter was per-
formed by the study officer in the clinic regardless of the TB
status of the participants.
Following positive serum CrAg results, lumbar puncture
(LP) was done for CrAg testing of cerebrospinal fluid (CSF).
The clinician prescribed treatment for OIs including TB and
cryptococcal meningitis (CM), isoniazid preventive therapy
(IPT) for TB contacts after ruling out TB, cotrimoxazole pre-
ventive therapy (CPT) for TB cases regardless of CD4 count
and contacts with CD4 < 350 cells/lL and fluconazole pre-
emptive therapy for patients with a positive serum CrAg but
no CM. All these interventions were performed at the same
single visit. After completing them, participants met again with
the study counsellor to discuss readiness for ART initiation.
Data collection of this single study visit was captured by the
clinical officer and counsellors with tablets using OpenDataKit
open-source data-capture software (Figure 1).
2.3 | ART initiation or ART adherence enforcement
On the same day or on the following day for those from most
remote locations, the study counsellor accompanied the
patient to their public HIV clinic. There, a report of the study
visit was delivered to the corresponding public officer for
them to make a decision on timing for OI treatment and ART
initiation. At this point, the role of the study counsellor was
limited to document patient registration, prescriptions and
patient picking-up of medication.
Participants included due to suboptimal ART adherence
were also escorted to their health units, where they were
booked for the routine government programme of adherence
counselling and plasma HIV viral load (VL) monitoring as rec-
ommended by the National ART guidelines [23,24].
2.4 | Follow-up visits
Participants were followed-up at their respective government
health units under routine programmatic conditions. The study
was limited to retrieve information from these clinics on visit
attendance and prescription refills of the participants. In case
a visit record was unavailable, the study counsellor made a
maximum of three attempts to trace the participant and
advise them to resume their clinic visits (Figure 1).
2.5 | Outcome definitions and mortality
Information on mortality was gathered from the existing
HDSS and death registries at each health unit. Loss-to-follow-
up (LTFU) was defined as failure to attend the six-month visit
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within a 30-day window. Attrition was defined as LTFU or
death before the sixth scheduled visit.
2.6 | Statistical analysis
Data were described by frequencies and median (interquartile
range, IQR) for discrete and continuous variables, respectively.
Cox regression was used to assess the effect of potential risk
factors on the probability of TB-index cases being retained in
care until the sixth month after enrolment. A multivariable
Cox proportional hazards model was obtained using a step-
wise procedure, starting with a model including variables with
clinical relevance defined from literature review (age, sex, sev-
ere anaemia, CrAg positivity, TB-LAM positivity and low CD4
count). These variables were kept in the model. Entry and
removal criteria for the remaining variables were based on
the p-value of the univariate analysis (<0.05 and >0.10 respec-
tively). The statistical significance level was set at 0.05. All
statistical analyses were conducted using Stata (StataCorp.
2019;StataCorp LLC., College Station, TX, USA).
3 | RESULTS
Between 28 May and 31 December 2018, 2881 adults were
visited in the Xpatial-TB intervention, including 546 TB-index
cases and 2335 of their contacts. Of those, 351 (64%) and
322 (14%) were HIV positive, respectively. Overall, eligibility
criteria for our ancillary intervention (newly HIV diagnosed,
ART na€ıve, suboptimal ART adherence and ART interrupters)
were met by 128 TB-index cases and 31 contacts. Of those,
98% (124/128) TB-index cases and all 31 contacts agreed to
enrolment (Figure 1). Of the TB-index cases, 86% (107/124)
were pulmonary TB (PTB), of whom 36% (38/107) had a posi-
tive Ultra result and 52% (65/124) were hospitalized at the
time of enrolment. All 31 contacts were ambulatory (Table 1).
Figure 1. Flow chart of interventions. Blue boxes, Xpatial-TB interventions. Green boxes, study-intervention. Yellow boxes, routine provision
of care in district ART units (government health centers). ALT, alanine-amino-transferase; ART, antiretroviral therapy; FBC, full blood count;
FU, follow-up; HCT, HIV counselling and testing; LTFU, lost to follow-up; M6, month six; OI, opportunistic Infections; POC, point of care;
TB-ACF, tuberculosis active case finding.
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3.1 | Characteristics of the study population and
prevalence of advance HIV disease
Since TB is a WHO stage 3 or 4 condition, all 124 TB-index
cases had AHD by definition. Additionally, other WHO stage 3
or 4 conditions were present in 76% (94/124) of TB index.
CD4 counts were <200 cells/lL in 70% (87/124). Of the 31
contacts, five (16%, 5/31) had a WHO stage 3 or 4 condition,
including four (13%, 4/31) with TB. Five contacts (16%, 5/31)
had <200 CD4 cells/lL. Only one contact met both clinical
and immunologic criteria. Overall, any AHD criteria were met
by 29% (9/31) of TB contacts (Table 1).
3.2 | Screening and diagnosis of tuberculosis
disease and cryptococcosis
Among TB-index cases, 78% (97/124) met TB-LAM testing
indications. Of those, 96% (93/97) were TB-LAM tested and
70% (65/93) had a positive result. TB-LAM was the only posi-
tive TB-test result in 51% (33/65) and 17% (10/59) of hospi-
talized and ambulatory TB-index patients, respectively. Overall,
Ultra was the only positive TB result in 11% (7/65) and 31%
(18/59) of hospitalized and ambulatory TB-index cases,
respectively. A CXR was done in 88% (109/124) of TB-index
participants, being interpreted as suggestive of TB in 81%
(88/109).
Among contacts, 23% (7/31) had a positive WHO-4SS.
Tuberculosis was diagnosed in four cases (4/31, 13%) includ-
ing one that was 4SS. One diagnosis was obtained only by
TB-LAM (4SS+), two only by Ultra (one 4SS+, one 4SS) and
one was clinically diagnosed (4SS+) with a suggestive CXR.
Serum CrAg screening result was available for all 92 eligible
participants (CD4 counts ≤200 cells/lL) and was positive in
4.9% (3/61) and 4.3% (4/92) of those with ≤100 and ≤200 CD4
cells/lL respectively. All four CrAg-positive cases were TB-index
patients and were performed a CSF-CrAg test that resulted neg-
ative in two of them (both were asymptomatic, including the par-
ticipant with >100 CD4 cells/lL) and positive in two cases that
had also disseminated TB and confirmed TB meningitis, respec-
tively. Both had severe neurological symptoms that had been
regarded as TB related prior to the serum CrAg-positive result.
3.3 | Prevention and treatment of opportunistic
infections
IPT was started for 93% (25/27) TB-free contacts. No new
episodes of TB were reported among participants. CPT was
provided to 98% (138/141) of cases with ≤350 CD4 cells/lL
or TB. Of the four plasma CrAg-positive participants, the two
with a negative CSF CrAg started fluconazole pre-emptive
therapy. Both were alive and under follow-up at the end of
the six-month follow-up. The two TB/CM co-infected (CSF-
Table 1. Characteristics of the study population
Variable
Participant type
Total (n = 155)TB-index cases (n = 124) TB contacts (n = 31)
Age, years 36.0 (30.6 to 44.5) 34.0 (27.0 to 39.7) 35.9 (29.9 to 43.8)
Male sex 72 (58) 11 (35) 83 (54)
Inpatient at recruitment 65 (52) 0 65 (42)
Body mass indexa, kg/m2 19.4 (17.5 to 21.5) 23.4 (20.8 to 25.6) 19.9 (17.9 to 23.0)
Haemoglobin < 8 g/dL 29 (23) 1 (3) 30 (19)
Abnormal ALT (≥1.5 ULN) 10 (8) 0 10 (6)
eGFR<60 mL/min/1.73 m2 20 (16) 0 20 (13)
CD4 cells/lL 105.0 (38.5 to 258.5) 355.0 (255.0 to 605.0) 132.0 (47.0 to 337.0)
Danger signs 75 (60) 2 (6) 77 (50)
ART status
New case 28 (23) 16 (52) 44 (28)
ART na€ıve 36 (29) 5 (16) 41 (26)
Suboptimal adherence 44 (35) 1 (3) 45 (29)
Interrupter 16 (13) 9 (29) 25 (16)
WHO stage
Stage 1 or 2 0 26 (84) 26 (17)
Stage 3 or 4 124 (100) 5 (16) 129 (83)
CD4 < 100 cells/lL 60 (48%) 1 (3%) 61 (39%)
CD4 < 200 cells/lLb 87 (70) 5 (16) 92 (59)
Advanced HIV diseasec 124 (100) 9 (29) 133 (86)
Data are shown as median (IQR) or n (%). ALT, alanine aminotransferase; eGFR, estimated creatinine glomerular filtration rate GFR (CKD-EPI for-
mula); ART, antiretroviral therapy; Danger signs, any of the following present: Heart rate >120 beats per minute, respiratory rate >30 breaths per
minute, Systolic blood pressure <90 mmHg, body temperature >39 Celsius, moderate or severe dehydration, bedridden or needing aid to walk,
altered mental state, other neurological problem.
an=153 (two missing values); bincludes also those with <100 cells/lL; cAHD defined as having CD4 < 200 cells/lL or WHO stage 3 or 4.
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CrAg+) continued antitubercular treatment and received
short-induction with amphotericin B-deoxycholate and high
dose fluconazole followed by six weeks of fluconazole consoli-
dation, after which they started ART and fluconazole mainte-
nance therapy. One was in good health at the end of study
follow-up, but the other died seven weeks after ART initiation.
The four contacts diagnosed with TB started on TB treatment
followed by timely ART initiation and were all alive at the end
of the study period.
3.4 | ART initiation
All 80 TB-index cases (80/124, 65%) and 30 contacts (30/31,
97%) that were not on ART at recruitment initiated or
resumed ART in the intervention. Of these, 84 TB cases,
including all 80 index cases and the four TB contacts diag-
nosed with TB delayed ART a median of 15 days (IQR 14 to
19) after initiation of antitubercular treatment. The two cases
with TB/CM started ART at day 38 and 54 respectively. All
TB-negative contacts initiated ART within 48 hours of their
recruitment (Figure 2).
3.5 | ART adherence re-enforcing
All 44 TB-index cases (44/124, 35%) and one contact (1/31,
3%) included in the study because of suboptimal ART adher-
ence were counselled and booked in their public clinics for
adherence re-enforcement counselling. None of the partici-
pants had been switched to second-line ART by the end of
the study follow-up. Public officers in district clinics reported
to the study that they had sent samples to Mozambique’s cap-
ital for VL determination as per national guidelines, but no
result had been recorded in the files during the six-month
study period.
3.6 | Retention and survival
Six-month mortality was 21% (26/124) in TB index of which
88% (23/26) occurred during admission and 0% (0/31) in
contacts. Six-month LTFU occurred in 14% (17/124) of TB
index and 16% (5/31) of contacts.
Male sex was the only independent predictor of attrition
identified (adjusted Hazard Ratio, aHR 2.18, 95% CI 1.10 to
4.34) adjusted by age, severe anaemia, CrAg positivity, TB-
LAM positivity and CD4 count. A trend was observed
between severe anaemia and increased hazard of attrition
aHR 2.01, 95% CI 0.97 to 4.17 (Table 2).
4 | DISCUSSION
The aim of this study was to describe the burden of advanced
HIV disease among TB-index cases and their contacts and to
assess the feasibility of implementing the WHO package of
interventions for AHD in this population. Key findings of the
study are as follows: (i) a high prevalence of AHD among HIV-
positive TB contacts (approximately 1/3rd); (ii) a CrAg preva-
lence over 4% among TB-index cases; (iii) TB-LAM was the
only positive TB test in half of TB inpatients (iv) almost 100%
initiation of IPT, CPT and fluconazole pre-emptive treatment
and 100% coverage of early ART initiation through a same-
day community intervention; (v) six-month attrition and mor-
tality comparable with that of historical records among TB
cases and no mortality among their HIV-positive contacts,
including those with AHD.
We nested an ancillary intervention into an existing
community-reach TB-case finding strategy (Xpatial-TB) that
was being assayed in a rural district in Mozambique. In seven
months, Xpatial-TB had reached 546 adult TB-index cases of
whom 351 (64%) were HIV co-infected. Over one-third of
these were newly HIV diagnosed, ART interrupters or had
suboptimal ART adherence (the present criteria defining our
target population). We visited these patients and found a 70%
prevalence of AHD based on CD4 counts. This finding aligns
with previous reports of suboptimal HIV control among the
TB/HIV population [25-31].
During the same timeframe, Xpatial-TB visited 2335 adult
TB contacts of whom 322 (14%) were HIV positive. Of them,
Figure 2. Time to ART-initiation. Daily cumulative proportion of participants (ART-na€ıve and ART interrupters) starting or resuming ART as
part of the intervention (‘treated’). Left, TB-free participants; Right, TB cases including TB-index and TB-contacts with TB. Four additional
TB-cases started ART 148, 148, 246 and 247 days after enrolment respectively.
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31 (10%) met the mentioned criteria, including 30 HIV-
positive contacts newly HIV diagnosed and one with subopti-
mal ART adherence. One-third of these HIV-positive TB con-
tacts had AHD (29%, 9/31), either immunologically defined
(CD4 <200 cells/lL in 5/9) and/or clinically defined (WHO
stage 3 or 4 found in 4/9). The overall proportion of AHD is
in line with other AHD surveys from the region [1-3]. TB pro-
gramme managers should factor in AHD screening and linkage
to care of HIV-positive TB contacts when discussing the effi-
ciency of community TB contact-tracing interventions, which
have been often regarded as low efficient when the benefit is
set only in their TB diagnosis yield [32-39].
CrAg prevalence was 4.3% and 4.9% in those with ≤200
and ≤100 CD4 cells/lL, respectively, similar to previous esti-
mates of prevalence of cryptococcosis among PLHIV in sub-
Saharan Africa (SSA) [7-9,40-42]. Of note, if we had used the
100 cells/lL threshold for screening, one out of four CrAg-
positive cases would have been missed. All CrAg-positive
cases were found among TB patients. When caring for TB/
HIV patients, TB officers are facing clinically defined AHD,
with a majority of these having low CD4 counts. However,
CrAg-screening, a cost-efficient life-saving intervention for
patients with AHD, is often missed in the integration of HIV
and TB services [28,43-47].
There was no pre-ART attrition in the study. Embedding the
intervention within TB-contact tracing and offering a full TB-
diagnostic work-up even for asymptomatic HIV-positive TB
contacts may have helped acceptance of the clinic visit. HIV
counsellors accompanied newly HIV-positive diagnosed partici-
pants throughout the day-long process leading up to the first
ART pick-up. Other studies have shown the importance of
similar escorting strategies to help linkage to care [48,49].
Finally, the same-day full pre-ART evaluation may have helped
pre-ART retention when compared to the standard process
that entails multiple visits [16,17,32,50,51].
Ninety percent of TB cases started or resumed ART within
eight weeks while all TB-free contacts did so within 48 hours
of the outreach intervention. Although evidence supports
same-day ART initiation, some studies have demonstrated
patient unreadiness or insufficient time to rule-out OIs prior
to rapid ART initiation [43,52-57]. Our experience shows that
patients’ counselling combined with use of POC-based OI-
testing is feasible for rapid ART initiation.
Fourteen percent of the study population failed to attend
their six-month visit within a 30-day window. Previous studies
in Mozambique with less stringent definitions reported higher
LTFU proportions [58-60].
Overall mortality in TB-index cases was 21%, which is in line
with the results of previous studies in the district [61,62]. The
vast majority of these deaths occurred among these TB/HIV
cases with AHD during hospital admission. The recommenda-
tions for AHD management may need to be tailored to the inpa-
tient population in order to further reduce its high mortality. By
contrast, six-month mortality among the 30 contacts starting
ART was zero. This is particularly relevant considering that 29%
met criteria for AHD at enrolment. Several reasons may
account for this. First, the contacts with TB were effectively
identified. Detecting TB and cryptococcal infection before ART
initiation is critical to avoid immune reconstitution inflammatory
syndrome (IRIS), a major cause of early post-ART initiation mor-
tality [5,8,9,11,25,35,63]. Of note, CrAg and TB-LAM study indi-
cations were broader than those recommended at the time and
performed among all patients with <200 cells/lL (regardless of
symptoms) to increase operationalization [4,21,64-70]. Finally,
all but two contacts received IPT, a life-saving intervention that
is still very low implemented [25,32,71-73].
The only independent predictor of attrition found was male
sex. We also found a moderate evidence in favour of an asso-
ciation between anaemia, a known predictor of mortality in
TB/HIV patients, and a two-fold increase in the hazard of
attrition, likely limited by the sample size [74-76]. TB-LAM
positivity and enrolment due to poor ART adherence were
also significantly associated with attrition in the univariable
analysis, both having been reported earlier [19,35,68,77-79].
The latter is a reminder of the alarming fact that today, ART-
experienced individuals account for 40% to 60% of AHD cases
presenting to care in SSA [1,37,65]. The small sample size
warrants a prudent interpretation of these findings.
Table 2. Factors associated with attrition in TB-index participants










Agea 0.99 (0.96 to 1.01) 0.297 0.98 (0.95 to 1.01) 0.149
Male sex 1.42 (0.77 to 2.62) 0.261 2.18 (1.10 to 4.34) 0.026
Severe anaemia (Hb <8 g/dL) 2.23 (1.20 to 4.18) 0.012 2.01 (0.97 to 4.17) 0.062
Renal insufficiency (eGFR < 60 mL/min) 1.13 (0.55 to 2.32) 0.732 – –
CrAg positivity 0.65 (0.15 to 2.75) 0.558 0.55 (0.12 to 2.55) 0.446
TB-LAM positivity 1.94 (1.05 to 3.60) 0.035 1.38 (0.67 to 2.85) 0.383
Cotrimoxazole preventive therapy 0.36 (0.05 to 2.70) 0.323 – – –
Low CD4 (<200 cells/lL) 1.96 (0.81 to 4.74) 0.133 1.72 (0.65 to 4.52) 0.271
Suboptimal adherence versus ART initiated 1.72 (0.94 to 3.14) 0.077 – –
Cox regression, crude model (left) and adjusted model (right). Number of subjects = 124. eGFR, Estimated creatinine glomerular filtration rate
GFR (CKD-EPI formula).
aPer unit increase.
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This study has some limitations. First, integrating our study
within an existing community-based TB-contact intervention
limits its replicability to similar conditions and may overesti-
mate AHD prevalence, due to the high TB burden of the tar-
get population (TB index and contacts). Second, the
community intervention would have greatly benefited from
POC strip tests discriminating above or below 200 CD4 cells/
lL on finger-prick samples [80,81]. This would have allowed
for off-clinic CD4 count testing, enabling a full home-based
POC strategy [19,32]. Also, for those on ART a HIV-VL POC-
assay should have followed in order to detect virological fail-
ure, beyond targeting those with suboptimal adherence.
[82,83]. The lack of POC-CD4 and POC-VL assays in our inter-
vention made it less sensitive and less specific to identify a
subgroup of HIV-positive individuals that could have greatly
benefitted from our intervention. Moreover, under routine
programmatic conditions, participants that were clear suspects
for ART failure (ART-experienced individuals with TB and/or
low CD4 counts) did not benefit from an ART switch during
the 6-month follow-up period. WHO recommends expedited
ART switch for AHD patients but this has not consistently
translated into national recommendations, rather, patients with
AHD usually endure the same long process of the general
HIV-positive population consisting of VL determinations
repeated every three months, which is challenging in districts
with non-existent VL-testing capacity [4,28,84-86]. The rollout
of multi-disease testing platforms such as GeneXpert which
has POC-VL capacity will increase the operationality of the
recommended “package of care” for ART-experienced patients
with AHD [87,88]. Third, we limited our ancillary intervention
to adults because the TB-contact tracing intervention (Xpatial-
TB) was already providing children with a provision of care far
exceeding the package recommended by the WHO for AHD.
Also, due to the limited sample size, we could only estimate
risk-factors of attrition in TB-index cases. Finally, our small
study sample limited our capacity to draw statistically signifi-
cant conclusions.
Our study has also several strengths. To our knowledge, it
is the first study attempting to use TB-ACF to find AHD cases
in the community. The WHO-recommended provision of care
was embedded within routine programmatic conditions in a
high HIV and TB burden area. Also, it provides the first pub-
lished estimates of CrAg prevalence among TB/HIV patients
in Mozambique. Moreover, TB diagnosis in HIV-positive TB
contacts was based on novel assays including Ultra and TB-
LAM, not always routinely available. Finally, this is the first
experience that we know reporting the capacity to achieve
same-day ART initiation in newly HIV-diagnosed TB contacts
reached in their communities.
5 | CONCLUSIONS
This study unveiled a high burden of AHD, TB and cryptococ-
cosis in a rural district of Mozambique and showed that TB
contact-tracing in communities offers an opportunity for TB-
HIV programmes to enhance detection and survival of HIV
patients by identifying AHD cases and providing them with
the WHO-recommended package of care. Same-day ART initi-
ation was possible and safe in HIV-positive TB-free contacts
with zero deaths among them. This POC-based intervention
exemplifies that comprehensive care provision is possible for
patients with AHD in rural settings. If taken to scale, this
strategy could contribute to reducing the still unacceptably
high AIDS-mortality in sub-Saharan Africa.
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